PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population-Reference-Cited by-同舟云学术

PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population

Published:2013-02 Issue:2 Volume:54 Page:561-566
ISSN:0022-2275
Container-title:Journal of Lipid Research
language:en
Short-container-title:Journal of Lipid Research

Author:

Postmus Iris,Trompet Stella,de Craen Anton J.M.,Buckley Brendan M.,Ford Ian,Stott David J.,Sattar Naveed,Slagboom P. Eline,Westendorp Rudi G.J.,Jukema J. Wouter

Publisher

Elsevier BV

Subject

Cell Biology,Endocrinology,Biochemistry

Reference24 articles.

1. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report;Circulation.,2002

2. Pharmacological strategies for lowering LDL cholesterol: statins and beyond;Brautbar;Nat Rev Cardiol.,2011

3. Clinical aspects of PCSK9;Cariou;Atherosclerosis.,2011

4. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition;Tibolla;Nutr. Metab. Cardiovasc. Dis.,2011

5. PCSK9: a promising therapeutic target for dyslipidemias?;Lambert;Trends Endocrinol. Metab.,2006

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Keeping translational research grounded in human biology;Journal of Clinical Investigation;2024-01-16

2. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system;Neuroscience & Biobehavioral Reviews;2023-06

3. Insight into the Evolving Role of PCSK9;Metabolites;2022-03-17

4. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy;Current Problems in Cardiology;2021-11

5. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression;International Journal of Cardiology;2021-07